Skip to main content

Non-Small Cell Lung Cancer


Thoracic small tissue specimens can provide adequate information for genomic profiling of the current guideline-recommended biomarkers for NSCLC, according to a recent study.
Conference Coverage
Study results show that immunotherapy is the most common next line of therapy after discontinuation of an EGFR-TKI and…
Conference Coverage
Treatment guided by biomarker testing is associated with improved survival outcomes in patients with advanced or…
Conference Coverage
Patients with NSCLC who receive pembrolizumab with chemotherapy are more likely to remain on therapy past 90 days than…
True or False: Higher out-of-pocket costs for TKIs among patients with epidermal growth factor receptor- and anaplastic…
Back to Top